Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Liabilities and Shareholders Equity (2016 - 2025)

Ligand Pharmaceuticals' Liabilities and Shareholders Equity history spans 16 years, with the latest figure at $1.5 billion for Q3 2025.

  • For Q3 2025, Liabilities and Shareholders Equity rose 54.66% year-over-year to $1.5 billion; the TTM value through Dec 2025 reached $3.3 billion, down 9.41%, while the annual FY2024 figure was $941.8 million, 19.63% up from the prior year.
  • Liabilities and Shareholders Equity for Q3 2025 was $1.5 billion at Ligand Pharmaceuticals, up from $948.6 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $1.5 billion in Q3 2025 and bottomed at $758.1 million in Q2 2023.
  • The 5-year median for Liabilities and Shareholders Equity is $948.6 million (2025), against an average of $1.0 billion.
  • The largest annual shift saw Liabilities and Shareholders Equity plummeted 41.22% in 2022 before it surged 54.66% in 2025.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $1.3 billion in 2021, then tumbled by 41.22% to $762.7 million in 2022, then increased by 3.22% to $787.2 million in 2023, then rose by 19.63% to $941.8 million in 2024, then skyrocketed by 56.81% to $1.5 billion in 2025.
  • Per Business Quant, the three most recent readings for LGND's Liabilities and Shareholders Equity are $1.5 billion (Q3 2025), $948.6 million (Q2 2025), and $905.4 million (Q1 2025).